Saudi Arabia to Open Stock Market to Foreign Financial Institutions – QFIs Rules Issued
Client Alert | 1 min read | 05.06.15
On July 22, 2014, the Saudi Arabian Capital Market Authority (CMA) announced that qualified foreign financial institutions (QFIs) would be permitted to buy and sell stocks listed on the Saudi stock market in accordance with rules to be adopted by the CMA. The CMA subsequently released its Draft Rules for Qualified Foreign Financial Institutions' Investment in Listed Shares (the Draft Rules) and solicited opinions and suggestions from investors and other interested parties on the Draft Rules.
On April 16, 2015, the CMA announced that it had adopted the following timeline to permit foreign financial institutions to buy and sell stocks listed on the Saudi stock market:
- Final Rules will be approved and published on 15/7/1436H (corresponding to May 4, 2015G);
- The Final Rules will be effective starting from 14/8/1436H (corresponding to June 1, 2015G); and
- QFIs shall be allowed to invest in listed shares starting from 28/8/1436H (corresponding to June 15, 2015G).
On May 4, 2015, the CMA issued its resolution Number 1-42-2015:
- Adopting the Rules for Qualified Foreign Financial Institutions Investment in Listed Shares (the QFIs Rules); and
- Adopting the following forms:
(a) Qualified Foreign Investor Application for Registration Form.
(b) Qualified Foreign Investor Client Application for Approval Form.
(c) The Minimum Requirements that must be included in the QFI Assessment Agreement Form as per Article 12 of the QFIs Rules.
(d) The Assessing Authorized Person's Acceptance Determination Template (to Register a QFI or to Approve a QFI Client).
(e) The Assessing Authorized Person's Rejection Determination Template (to Register QFI or to Approve QFI Client).
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today